长春瑞滨联合吉西他滨治疗晚期乳腺癌50例临床分析

目的 观察长春瑞滨（NVB）联合吉西他滨（GEM）治疗蒽环类和紫杉类药物耐药的晚期乳腺癌患者（ATRMBC）的临床效果. 方法 采用NVB联合GEM方案（GN方案）治疗50例蒽环类和紫杉类药物耐药的晚期乳腺癌患者,NVB 25 mg/m2静脉滴注,第1、8天;GEM 1 000 mg/m2静脉滴注,第1、8天;21 d为1个周期,最多接受6个周期的化疗. 结果 50例患者完全缓解2例（4%）,部分缓解19例（38%）,稳定22例（44%）,进展7例（14%）;有效率42%;平均随访17.2个月,中位生存期16.8个月.主要不良反应为恶心、呕吐及骨髓抑制. 结论 NVB联合GEM是治疗蒽环类和紫杉类药物耐药的晚期乳腺癌患者的有效方案,患者对不良反应能够耐受.

Clinical analysis of vinorelbine combined with gemcitabine for treatment patients with anthracycline and Taxane-refractory metastatic breast cancer

Objective To evaluate the clinical efficacy and adverse reaction induced by vinorelbine(NVB)combined with gemcitabine(GEM)for patients with anthracycline and taxane-refractory metastatic breast cancer(ATRMBC). Methods 50 ATRMBC patients were enrolled in this study.They received a combined therapy including NVB and GEM(GN regimen).NVB was intravenously infused at 25mg/m2 and GEM was intravenously infused at 1000 mg/m2 on day 1 and day 8.Twenty-one days were regarded as one cycle.Maximum 6 cycles were given. Results Two patients(4%)achieved a complete response,19 patients(38%)had a partial response,with an overall Objective response rate of 42%.Stable disease was documented in 22 patients(44%)while progressive disease occurred in 7 patients(14%).After average follow-up for 17.2 months,and the median overall survival time was 16.8 months.The main toxicities were nausea,vomiting and myelo suppression. Conclusion NVB combined with GEM could be effective for ATRMBC patients.The adverse reaction could be tolerated by patients.